Decreased Survival of B Cells of HIV-viremic Patients Mediated by Altered Expression of Receptors of the TNF Superfamily by Moir, Susan et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
The Journal of Experimental Medicine • Volume 200, Number 5, September 6, 2004 587–599
http://www.jem.org/cgi/doi/10.1084/jem.20032236
 
587
 
Decreased Survival of B Cells of HIV-viremic Patients 
Mediated by Altered Expression of Receptors 
of the TNF Superfamily
 
Susan Moir,
 
1
 
 Angela Malaspina,
 
1
 
 Oxana K. Pickeral,
 
2
 
 Eileen T. Donoghue,
 
1
 
 
Joshua Vasquez,
 
1
 
 Natalie J. Miller,
 
1
 
 Surekha R. Krishnan,
 
2 
 
Marie A. Planta,
 
1
 
 
John F. Turney,
 
1
 
 J. Shawn Justement,
 
1
 
 Shyamasundaran Kottilil,
 
1
 
 Mark Dybul,
 
1
 
 
JoAnn M. Mican,
 
1
 
 Colin Kovacs,
 
3
 
 Tae-Wook Chun,
 
1
 
 Charles E. Birse,
 
2
 
 
 
and Anthony S. Fauci
 
1
 
1
 
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of 
Health, Bethesda, MD 20892
 
2
 
Human Genome Sciences Inc., Rockville, MD 20850
 
3
 
Department of Medicine, University of Toronto, Toronto, Ontario M5S 1A1, Canada 
 
Abstract
 
Human immunodeficiency virus (HIV) infection leads to numerous perturbations of B cells
through mechanisms that remain elusive. We performed DNA microarray, phenotypic, and
functional analyses in an effort to elucidate mechanisms of B cell perturbation associated with
ongoing HIV replication. 42 genes were up-regulated in B cells of HIV-viremic patients when
compared with HIV-aviremic and HIV-negative patients, the majority of which were inter-
feron (IFN)-stimulated or associated with terminal differentiation. Flow cytometry confirmed
these increases and indicated that CD21
 
low
 
 B cells, enhanced in HIV-viremic patients, were
largely responsible for the changes. Increased expression of the tumor necrosis factor (TNF)
superfamily (TNFSF) receptor CD95 correlated with increased susceptibility to CD95-mediated
apoptosis of CD21
 
low
 
 B cells, which, in turn, correlated with HIV plasma viremia. Increased
expression of BCMA, a weak TNFSF receptor for B lymphocyte stimulator (BLyS), on
CD21
 
low
 
 B cells was associated with a concomitant reduction in the expression of the more
potent BLyS receptor, BAFF-R, that resulted in reduced BLyS binding and BLyS-mediated
survival. These findings demonstrate that altered expression of genes associated with IFN stim-
ulation and terminal differentiation in B cells of HIV-viremic patients lead to an increased pro-
pensity to cell death, which may have substantial deleterious effects on B cell responsiveness to
antigenic stimulation.
Key words: terminal differentiation • interferon • immune activation • 
gene expression • microarray
 
Introduction
 
HIV infection is associated with numerous immunologic
deficiencies, several of which are paradoxically associated
with immune hyperactivation induced by ongoing viral
replication. The aberrant immune activation induced by
HIV represents a systemic effect that is best illustrated by
the profound effects of HIV on B cells and CD8
 
 
 
 T cells
(1–3), two populations of lymphocytes that are not direct
targets for productive HIV replication. Although B cells
have been shown to carry replication-competent HIV virions
on their surface via CD21–C3d immune complex interac-
tions (4), the relatively low frequency of such cells is far below
the percentage of B cells whose function is altered in the
presence of ongoing HIV replication, suggesting a prepon-
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derance of indirect over direct effects of the virus on B cells
of infected individuals. The most prominent B cell defects
associated with HIV infection include hypergammaglobu-
linemia (5–7), increased expression of markers of activation
and terminal differentiation (8–10), increased secretion of
immunoglobulins in vitro (11), decreased response to B cell
activators in vitro and in vivo (12–16), and increased sus-
ceptibility to apoptosis (17, 18). With the availability of ef-
fective antiretroviral therapy, it has been possible to dem-
onstrate that most of these B cell defects are directly
associated with high levels of HIV plasma viremia. Several
longitudinal and cross-sectional studies have shown that re-
duction of HIV plasma viremia leads to normalization of B
cell activities, as evidenced by reductions in polyclonal and
HIV-specific Ig levels (6, 9, 19–22), restoration of APC
function and responsiveness to CD4
 
 
 
 T cell help (10, 16),
and normalization of expression of B cell markers of activa-
tion and terminal differentiation (9, 10, 23).
Although there is widespread consensus that HIV infec-
tion leads to B cell dysfunction, the underlying mechanisms
and nature of the dysregulation remain poorly understood.
Our previous findings suggested that the hypergammaglob-
ulinemia observed in HIV-infected viremic patients re-
sulted from stimulation of B cell terminal differentiation by
HIV-mediated immune activation (9). However, others
have proposed that depletion of memory B cells and conse-
quent enrichment of activated naive B cells are the basis for
B cell immune dysfunction in HIV-infected patients (23).
Our proposal for B cell terminal differentiation was based
primarily on the observation that patients who did not sup-
press their HIV viremia had an increased percentage of B
cells that expressed reduced levels of CD21, a marker that
has been shown to decrease with differentiation toward the
plasma cell phenotype (24). The subpopulation of B cells
expressing reduced levels of CD21 was also found to pos-
sess plasmacytoid features not found in the CD21
 
high
 
 frac-
tion and was also shown to secrete high levels of immuno-
globulins and respond poorly to B cell proliferative signals
(9). The loss of cell surface CD21 was also associated with
decreased levels of CD21 mRNA, further suggesting that
the CD21
 
low
 
 fraction was associated with B cell terminal
differentiation (25), rather than ligand-induced receptor
depletion. However, other features of B cell terminal dif-
ferentiation, such as loss of surface Ig expression and other
surface markers such as HLA-DR, CD20, and CD19 were
not consistently observed on B cells of HIV-viremic pa-
tients, suggesting either that HIV-induced immune activa-
tion induces partial terminal differentiation or that a com-
pletely unique pathway of aberrant B cell activation occurs
in HIV infection.
Considering the current uncertainties associated with
HIV-mediated B cell dysfunction, we embarked on a study
that began with the analysis of gene expression profiles in B
cells of HIV-viremic patients, led to a comprehensive anal-
ysis of B cell markers associated with reduced CD21 ex-
pression, and culminated in analyses associated with altered
expression of members of the TNF superfamily (TNFSF)
of receptors. The data presented in this paper strongly sug-
gest that HIV viremia leads to alterations in the expression
of TNFSF receptors on B cells, rendering these cells more
susceptible to cell death. These findings present a complex
picture of survival and death in B cells and how HIV infec-
tion can shift this delicate balance and lead to profound
dysfunction of the B cell arm of the immune response.
 
Materials and Methods
 
Study Subjects. 
 
Three groups of individuals were investigated:
patients chronically infected with HIV whose plasma viremia was
 
 
 
10,000 copies of HIV RNA/ml, patients chronically infected
with HIV whose plasma viremia was 
 
 
 
100 copies of HIV RNA/
ml, and HIV-negative donors. HIV-viremic patients were either
antiretroviral therapy-naive, not fully compliant with their antiret-
roviral regimen, or failing therapy, whereas the HIV-aviremic
patients were receiving effective antiretroviral regimens. Leuka-
pheresis and blood draws were conducted in accordance with pro-
tocols approved by the Institutional Review Boards of the
University of Toronto and the National Institute of Allergy and
Infectious Diseases (NIAID) at the National Institutes of Health.
 
Cell Preparation and Cell Surface Marker Analyses. 
 
PBMCs
were obtained from leukapheresis or blood draws by Ficoll den-
sity gradient centrifugations. B cells were isolated from PBMCs
by negative selection using an immunomagnetic column-based
technique (StemCell Technologies Inc.). The purity of each B
cell preparation, typically 
 
 
 
95%, was verified as described previ-
ously (4). PE-labeled mAbs were purchased from BD Biosciences
or R&D Systems. FITC-labeled anti-CD21 was purchased from
Beckman Coulter. Streptavidin-PE, biotin-labeled anti-BCMA,
and anti-TACI, as well as unlabeled goat anti-BAFF-R Abs,
were purchased from R&D Systems. PE-labeled swine anti–goat
was purchased from Caltag. B lymphocyte stimulator (BLyS; Hu-
man Genome Sciences) was biotinylated with NHS-LC-biotin
(Pierce Chemical Co.) according to the manufacturer’s recom-
mendations. Negative controls included isotyped-matched mAbs
for direct stains and omission of the first Ab for indirect stains.
Stained cells were analyzed on a FACSCalibur flow cytometer
(BD Biosciences).
 
DNA Microarray Analyses of Gene Expression. 
 
Total RNA
was isolated from 5–10 
 
 
 
 10
 
6
 
 purified B cells using TRIzol (In-
vitrogen) according to the manufacturer’s specifications. Hybrid-
ization and DNA microarray analyses were performed as
described previously (26). 
 
33
 
P-labeled first-strand cDNA was syn-
thesized from 5 
 
 
 
g of total RNA. cDNA probes were hybridized
to DNA arrays comprised of 6,476 genes enriched in clones that
had high-quality RefSeq matches. After extensive washing under
stringent conditions, the hybridization signal was detected after a
60-h exposure using a FUJI BAS 2500 phosphorimaging system
and captured and quantitated using ImaGene 4.0 software (Bio-
Discovery). After linear normalization to total signal, low expres-
sion values were assigned a low signal of 35, which represents the
98th percentile of blank spots, to avoid potential overinterpreta-
tion of low-signal changes. Only the data points with a coeffi-
cient of variation 
 
 
 
0.8 for duplicate spots were included in fur-
ther analyses. The data were log(2) transformed, and each gene
expression profile among all HIV-viremic, HIV-aviremic, and
HIV-negative patients was median centered.
 
B Cell Apoptosis Assay. 
 
Freshly isolated B cells, or enriched
CD21
 
low
 
 and CD21
 
high
 
 subsets (9), were maintained at 4
 
 
 
C or
were incubated at 37
 
 
 
C for 2 and 16 h in RPMI 1640 medium 
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plus 10% FCS in the presence or absence of 1 
 
 
 
g/ml FLAG-
tagged Fas ligand (FasL; Kamiya Biomedical) or 800 ng/ml BLyS.
Cells were collected, washed, resuspended in annexin V binding
buffer (BD Biosciences), stained with FITC-labeled annexin V,
and PE-labeled anti-CD21 mAb (Biosource International) ac-
cording to the manufacturer’s specifications for Apoptosis Detec-
tion Kit 1 (BD Biosciences).
For effect of HIV on Fas-mediated apoptosis, autologous virus
was recovered from CD4
 
 
 
 T cells of HIV-viremic patients by
coculture with PBMCs from HIV-negative donors as described
previously (4), and the virus was clarified and concentrated by ul-
trafiltration. B cells were incubated with or without FasL in the
presence of concentrated virus or concentrated supernatant from
PBMCs alone to control for non-HIV effects.
 
Statistical Analysis. 
 
Group comparisons for surface marker
expression on bulk B cells were performed using the nonpara-
metric analysis of variance Kruskal-Wallis test with Dunn’s multi-
ple comparison tests for medians. The Spearman rank method
was used to test for correlation and adjustment of p-values for
multiple testing was done with the Bonferroni method. The dif-
ferences in cell surface marker expression and BLyS-binding ef-
fects relative to CD21 were compared by the two-tailed Wil-
coxon signed-rank test.
 
Online Supplemental Material.
 
Additional B cell surface
marker staining and comprehensive analyses of all markers
are presented in Fig. S1 and Table S1. Online supplemental
material is available at http://www.jem.org/cgi/content/full/
jem.20032236/DC1.
 
Results
 
Up-Regulation of Genes Associated with IFN Stimulation and
Terminal Differentiation in B Cells of HIV-viremic Patients.
 
To establish B cell gene expression profiles associated with
HIV infection, we analyzed PBMC-derived B cells from
three different groups of individuals: 10 HIV-infected pa-
tients who controlled their plasma viremia with antiretrovi-
ral therapy (HIV-aviremic patients), 10 HIV-infected pa-
tients with similar CD4
 
 
 
 T cell counts but who did not
control their plasma viremia (HIV-viremic patients), and
10 HIV-negative healthy donors. The DNA microarray
data were analyzed by establishing the genes that were dif-
ferentially regulated in one group relative to the two other
groups. By far, the highest number of differentially ex-
pressed genes was observed when B cells of HIV-viremic
patients were compared with the B cells of the HIV-
aviremic and the HIV-negative patients. Those genes
found to be up-regulated in B cells of HIV-viremic patients
compared with the two other groups are shown in Fig. 1.
Approximately 75% of the genes listed in Fig. 1 can be cat-
egorized into one of two functional groups: IFN-stimu-
lated genes (ISGs) and genes associated with B cell activi-
ties. Of the 14 B cell–related genes, 10 were associated
with B cell terminal differentiation and, whereas two of the
remaining genes, F
 
 
 
1 and the IgH enhancer sequence
Figure 1. Genes up-regulated greater than twofold in B cells of 10 HIV-viremic patients compared with 10 HIV-aviremic patients and 10 HIV-negative
donors. The results depict all genes whose profiles were significantly different between HIV-viremic patients and the other groups of individuals
(grouped together), as evaluated by T-statistics. The genes are ordered by the ratio of mean values between these two groups and represent one out of
two independent hybridizations. A cut-off of twofold was used to produce this gene set. Relative levels of gene expression (median-centered normalized
expression values) are shown in color according to the scale at the bottom, where red indicates up-regulation and green indicates down-regulation. Data
points with CV  0.8 are depicted in gray. The categories of B and B-TD refer to genes associated with B cell activities and B cell terminal differentia-
tion, respectively. The values in the column on the left represent median signal intensities obtained after linear normalization and averaging of duplicate
spot signals for each clone. 
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found in sterile transcripts preceding gene rearrangement
(27), would appear consistent with a more immature phe-
notype, both have been associated with mature B cell ac-
tivities. Increased F
 
 
 
1 transcription has been observed dur-
ing the germinal center reaction (28, 29), whereas IgH
enhancer-containing transcripts have been associated with
class switching (30) and isolated from germinal center–
derived B cells (GenBank/EMBL/DDBJ accession nos.
AW402612 and AA280858). As for the other two B cell–
related genes, CD11b and synapsin III, both have been as-
sociated with B cell activities (28, 31), although it is cur-
rently unknown why they would be overexpressed in B
cells of HIV-viremic patients. Overall, these data illustrate
both the classic effects of a viral infection on cells of the
immune system (32) as shown by the abundance of ISGs,
and the unique effect of HIV on B cells (9), as shown by
the genes associated with terminal differentiation, including
various surface markers (see next paragraph), proteins of
secretory pathways, and immunoglobulin-related genes. Of
the 17 ISGs found to be up-regulated in B cells of HIV-
viremic patients, 9 were identical to genes induced by
treatment of cells with IFNs (33) and 5 were identical to
those found to be up-regulated in systemic lupus erythema-
tosus (SLE; reference 34), an inflammatory disease that has
similarities with HIV infection with regard to perturbations
of B cells. Of note, five of the ISGs are also associated with
lupus inclusions, intracellular formations found in B cells
after treatment with type I IFNs (35), and in lymphoid tis-
sues of HIV-infected patients (36). Several genes up-regu-
lated in B cells of HIV-viremic patients were also found to
be up-regulated in multiple myeloma, including BCMA,
CXCR3, and annexin A2 (37). Considering that multiple
myeloma is a B cell neoplasm characterized by expansion of
plasma cells, these similarities in gene expression profiles
further implicate terminal differentiation as a mechanism of
B cell perturbation in HIV-viremic patients.
 
Up-regulated Genes for B Cell Surface Markers Are Correlated
with CD21
 
low
 
 Population.
 
Several of the genes shown in
Fig. 1 encode cell surface proteins, including BCMA,
CD95, CD38, CXCR3, and CD11b. Increases in expres-
sion of BCMA, CD38, and CXCR3 have been associated
with terminal differentiation of B cells (38–40), whereas
CD95, also known as Fas, has been associated with IFN
stimulation (33). To determine whether the up-regulation
of genes of these B cell surface markers was linked to our
previous observations regarding expression of CD21 (9),
we evaluated the expression of each B cell marker relative
to CD21 expression. Although it was impossible to per-
form the gene expression analyses on B cells fractionated
into CD21
 
low
 
 and CD21
 
high
 
 subpopulations due to the pau-
city and fragility of cells after cell sorting, we took advan-
tage of multicolor flow cytometry to analyze the expression
of the various B cell markers of interest relative to CD21.
As illustrated in Fig. 2 by analyses of a representative pa-
tient in each group, expression of BCMA, CD95, and
CD38 was increased on B cells of HIV-viremic patients
when compared with the representative HIV-aviremic pa-
tient and HIV-uninfected donor. Furthermore, the in-
creased expression of these receptors was predominantly as-
sociated with the CD21
 
low
 
 population, a population that
was marginally present in B cells of HIV-aviremic and
HIV-uninfected patients. Although not as dramatic, similar
Figure 2. Phenotyping of B cell markers found to be
up-regulated in HIV-viremic patients by microarray analyses.
A gate was set on CD19-positive B cells, and cells were
analyzed for expression of BCMA, CD95, and CD38 rela-
tive to CD21. Representative profiles from an HIV-viremic
patient, an HIV-aviremic patient, and an HIV-negative in-
dividual are shown. Inset values shown for CD95 and CD38
represent percentage of B cells expressing high-intensity
receptors delineated by the top horizontal bar. 
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Figure 3. Flow cytometric analysis
of BCMA (A), CD38 (B), and
CD95 (C) expression relative to
CD21 on B cells. Levels of expres-
sion measured by gating on CD19-
positive B cells are shown for nine
HIV-viremic patients, eight HIV-
aviremic patients, and nine HIV-
negative individuals. 
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patterns were observed for CXCR3 and, to a lesser extent,
CD11b (unpublished data), observations that were consis-
tent with the gene expression profiles in Fig. 1.
A more extensive validation of the microarray data was
sought by extending the flow cytometric analyses illustrated
in Fig. 2 to include the majority of the patients whose gene
expression profiles are shown in Fig. 1. We not only con-
centrated on the genes that were found to be elevated by
microarray analysis but also on B cell markers that could
help us better determine the state of differentiation of the B
cells. BCMA, described previously as an intracellular pro-
tein in B cells (41), was consistently up-regulated on the
CD21
 
low
 
 fraction of B cells enriched in HIV-viremic pa-
tients yet consistently absent from the surface of CD21
 
high
 
B cells (Fig. 3 A and Table S1, available at http://www.
jem.org/cgi/content/full/jem.20032236/DC1), and levels
of BCMA expression on B cells of HIV-viremic patients
were significantly higher than on B cells of HIV-aviremic
patients (P 
 
 
 
 0.001) and HIV-negative donors (P 
 
 
 
 0.01).
A slightly different approach was used to demonstrate
differences in levels of expression of CD95 and CD38; it
is the high-density surface expression of each of these
receptors that appears to be important for susceptibility
to apoptosis and association with terminal differentiation,
respectively (42, 43). Although CD38 was expressed on
a high percentage of B cells in all three categories of pa-
tients studied, expression of high-intensity CD38 was in-
creased on B cells of viremic patients compared with the
other two groups (P 
 
 
 
 0.01), with CD21
 
low
 
 B cells ac-
counting for the majority of the increases (Fig. 3 B and Ta-
ble S1). When CD95 levels were analyzed, a similar pattern
of expression was observed (Fig. 3 C and Table S1).
CD21
 
low
 
 B cells of HIV-viremic patients were found to ex-
press very high levels of CD95 when compared with their
CD21
 
low
 
 counterpart (P 
 
 
 
 0.001), and levels of CD95 ex-
pression on B cells of HIV-viremic patients were signifi-
cantly higher than on B cells of HIV-aviremic patients
(P 
 
 
 
 0.05) and HIV-negative donors (P 
 
 
 
 0.001). Other
distinctive patterns relative to CD21 expression included
significantly decreased levels of CD20, CD22, CD124 (IL-4
receptor), and CD25 on CD21
 
low
 
 B cells and significantly
increased levels of CD27, CD80, CD86, CXCR3, and
Figure 4. B cell responses to FasL. B cells were incubated at
4 C or at 37 C with and without FasL for 2 h and stained for
CD21 and annexin V. (A) FACS® plots on live-gated cells are
shown for a representative HIV-viremic patient, HIV-
aviremic patient, and HIV-negative individual (see Table S1
for complete dataset). Correlation between percentage of an-
nexin V staining in B cells where levels of staining without
FasL were subtracted from levels with FasL and (B) percentage
of CD95 expression on B cells or (C) levels of HIV plasma
viremia in the HIV-infected patients (limit of detection was 50
copies/ml of plasma). 
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high-intensity CD22 on CD21
 
low
 
 B cells (Fig. S1, available
at http://www.jem.org/cgi/content/full/jem.20032236/
DC1, and Table S1). These patterns of expression were
consistent with previous observations made on B cells of
HIV-viremic patients, including increased activation (CD80
and CD86; reference 10), decreased function (CD25; refer-
ences 10, 16), and induction of terminal differentiation
(CD20, CD25, CD27, and CXCR3; references 38, 39). It
should be noted that for CD20 and CD27, changes in ex-
pression were not as pronounced as reported for plasma
cells, and often missed if the analyzed cells came from cryo-
preserved samples (9). However, these changes were always
present to some degree on the CD21
 
low
 
 fraction of B cells
of HIV-viremic patients, and easier to establish with a weak
fluorochrome such as FITC (Fig. 2 and Fig. S1) compared
with a strong one such as PE (9). Collectively, these phe-
notypic data validate the microarray data and extend
our previous findings by demonstrating that the CD21
 
low
 
 B
cells are largely responsible for the alterations observed in
HIV-viremic patients.
 
Increased Expression of CD95 Correlates with Increased Sus-
ceptibility to Fas-mediated Apoptosis. 
 
Having demonstrated
that CD21
 
low
 
 B cells of HIV-viremic patients express aber-
rantly high levels of CD95, we sought to determine
whether this subset was more prone to Fas-mediated apop-
tosis when compared with its CD21
 
high
 
 counterpart and B
cells of HIV-aviremic patients and HIV-negative donors.
To this end, B cells were incubated with or without solu-
ble FasL for 2 h and stained with annexin V and anti-CD21
mAb. As demonstrated in Fig. 4 A by comparing cells in-
cubated at 4
 
 
 
and 37
 
 
 
C, B cells of the HIV-viremic patient
were far more prone to spontaneous apoptosis than were B
cells of the other two categories of patients and, further-
more, most of the apoptotic cells belonged to the CD21
 
low
 
subset of B cells. The addition of FasL further increased the
level of apoptosis in B cells of HIV-viremic patients, and
again the apoptotic cells were largely restricted to the
CD21
 
low
 
 subset of B cells that was over-represented in
HIV-viremic patients. In HIV-aviremic patients and HIV-
negative donors, addition of FasL induced marginal levels
of apoptosis (Fig. 4 A). When data were collected on sev-
eral individuals in each category, a direct correlation was
found between the level of CD95 expression and the level
of apoptosis induced by FasL (P 
 
 
 
 0.0001; Fig. 4 B). Fur-
thermore, when levels of HIV plasma viremia for each
HIV-infected patient were plotted against Fas-mediated
apoptosis, these two parameters were directly correlated
(P 
 
 
 
 0.001; Fig. 4 C). Given that triggering of the BCR
has been shown to reverse Fas-mediated apoptosis in B cells
(44), we tested whether the triggering of HIV-specific B
cells by autologous virus could lead to protection from Fas-
mediated apoptosis. Of four viremic patients tested, evi-
dence for protection from Fas-mediated apoptosis was ob-
served in one patient and only when the concentration of
HIV p24 antigen was 
 
 
 
1 
 
 
 
g/ml (unpublished data), which
is 10,000 times above the highest levels reported in plasma
(45). Hence, it is highly unlikely that the presence of virus
in vivo can protect B cells of HIV-viremic patients from
Fas-mediated apoptosis. Collectively, these observations
demonstrate that B cells of HIV-viremic patients, and in
particular the CD21
 
low
 
 population, are more prone to spon-
taneous and Fas-mediated apoptosis than are B cells of
HIV-aviremic patients and HIV-negative donors.
 
B Cells of HIV-viremic Patients Express Increased Levels of
BCMA and TACI and Decreased Levels of BAFF-R. 
 
The
microarray (Fig. 1) and phenotypic (Figs. 2 A and 3 A)
analyses indicated increased expression of BCMA, one of
three known receptors for BLyS (also known as BAFF,
Figure 5. Representative ex-
pression of BCMA, TACI, and
BAFF-R, as well as BLyS-binding,
on B cells of HIV-viremic, HIV-
aviremic, and HIV-negative in-
dividuals. A gate was set on
CD19-positive B cells, and cells
were analyzed for expression of
BCMA, TACI, and BAFF-R
relative to CD21. Representative
profiles from an HIV-viremic
patient, an HIV-aviremic patient,
and an HIV-negative donor are
shown (see Table S1 for com-
plete dataset). 
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TALL-1, THANK, zTNF4, or TNFSF13b; reference 41),
in and on B cells of HIV-viremic patients. Although the
genes for the two other receptors for BLyS, namely BAFF-R
and TACI, were not on the array used in this hybridiza-
tion, we analyzed each receptor by flow cytometry. When
levels of BCMA, TACI, and BAFF-R were measured on B
cells from the three groups of patients, a clear trend was
observed that contrasted B cells of HIV-viremic patients
with those of HIV-aviremic and HIV-negative donors
(Fig. 5). Consistent with data shown in Figs. 2 A and 3 A,
BCMA expression was restricted to the CD21
 
low
 
 popula-
tion of the HIV-viremic patient. Expression of TACI was
found to be more variable. However, overall, the B cells of
HIV-viremic patients expressed significantly more TACI
than did B cells of HIV-aviremic and HIV-negative donors
(Table S1), and CD21
 
low
 
 B cells of HIV-viremic patients
expressed significantly more TACI than did their CD21
 
high
 
counterparts. Finally, significantly lower levels of BAFF-R
were observed on B cells of HIV-viremic patients when
compared with B cells of HIV-aviremic and HIV-negative
donors (Fig. 5 and Table S1). The loss in BAFF-R expres-
sion was largely seen among CD21
 
low
 
 B cells of the HIV-
viremic patients with a median of 76.3% of CD21
 
low
 
 B cells
expressing BAFF-R compared with 96.3% for CD21
 
high
 
 B
cells (Fig. 6 A and Table S1; P 
 
 
 
 0.001). Collectively,
these data suggest that B cells of HIV-viremic patients, and
in particular their CD21
 
low
 
 B cells, tend to express in-
creased levels of BCMA and TACI and decreased levels of
BAFF-R. These data are consistent with findings of a
recent paper (40), where the same pattern of increased
BCMA and TACI and decreased BAFF-R expression was
observed when B cells were differentiated into plasma cells
in vitro, a process that is thought to occur in vivo in HIV-
infected viremic patients (9).
The significance of the modulations in the expression of
BCMA, TACI, and BAFF-R on B cells of HIV-viremic
patients was investigated relative to ligand binding and
ligand-mediated functional effects. Although BLyS has
been shown to bind all three receptors, BAFF-R is thought
to be the receptor with the highest affinity (46). Consistent
with this observation, we found that regardless of the pro-
file of expression of BCMA and TACI, BLyS-binding on B
cells mirrored BAFF-R expression (Fig. 5). The significant
reduction of BAFF-R expression on CD21
 
low
 
 B cells of
viremic patients was also observed for BLyS-binding (Fig. 6
B and Table S1; P
 
 
 
 
 
 0.001) and, furthermore, there was a
significant correlation between BAFF-R expression and
BLyS-binding on B cells of HIV-viremic patients (r 
 
 
 
0.69, P 
 
 
 
 0.005; not depicted). Finally, we sought to
determine whether the decrease in BLyS-binding on
CD21
 
low
 
 relative to CD21
 
high
 
 B cells had an impact on the
responsiveness of these B cell fractions to BLyS. One of the
major effects of BLyS on mature B cells is to promote cell
survival by preventing apoptosis (47). Accordingly, B cells
of HIV-viremic patients, known to be highly susceptible to
spontaneous apoptosis (Fig. 4 A and references 17, 18),
were fractionated into CD21
 
low
 
 and CD21high subsets and
incubated with and without BLyS for 16 h. As shown in
Fig. 6 C, the survival effect of BLyS was significantly more
pronounced on CD21high compared with CD21low B cell
fractions (P   0.01) and, furthermore, there was a signifi-
cant correlation between the differences in BLyS-binding
between the two fractions and their responsiveness to BLyS
(r   0.66, P   0.05; not depicted). Together, these data
demonstrate that loss of BLyS-binding on B cells of HIV-
viremic patients is largely restricted to the CD21low B cell
population that in turn translates into a loss in BLyS-medi-
ated survival.
Discussion
In the present work, we extend our understanding of
how HIV viremia leads to aberrant activation of B cells, as
evidenced by hypergammaglobulinemia (5–7), increased
Figure 6. Levels of (A) BAFF-R
expression and (B) BLyS-binding
on CD21low versus CD21high B
cells of HIV-viremic patients.
Levels of BAFF-R expression and
BLyS-binding were measured on
CD19-gated B cells of 16 HIV-
viremic patients and are expressed
as the percentage of BAFF-R
expression on the CD21low and
CD21high populations for each
patient. (C) Survival effect of
BLyS measured on B cells of
HIV-viremic patients fractionated
into CD21low and CD21high sub-
sets. The percent survival after 16 h
incubation was calculated as the
fraction of annexin-positive cells
measured in the presence of
BLyS over annexin-positive cells
measured in the absence of BLyS
multiplied by 100.Moir et al. 595
expression of activation markers (8, 10), and increased sus-
ceptibility to apoptosis (17, 18), by demonstrating that B
cells of HIV-viremic patients up-regulate numerous genes
associated with IFN stimulation and terminal differentia-
tion. We also provide evidence of a unique intersection be-
tween these two pathways and our previous findings show-
ing reduced expression of CD21 on B cells of HIV-viremic
patients (9). Although the previous paper suggested that
loss of CD21 expression, both at the protein and transcrip-
tion levels, and concomitant increases in immunoglobulin
secretion, decrease in proliferative potential, and appear-
ance of plasmacytoid features were associated with terminal
differentiation, the current work adds additional dimen-
sions of dysfunction. CD95, an apoptosis marker that is not
strongly modulated during B cell terminal differentiation
(38, 48), but is up-regulated as a result of IFN stimulation
(33), was markedly up-regulated on CD21low B cells of
HIV-viremic patients. Furthermore, by showing that
CD21low B cells were considerably more prone to Fas-
mediated apoptosis than were their CD21high counterpart
and B cells of HIV-aviremic patients and HIV-negative do-
nors, and by demonstrating that there was a direct correla-
tion between Fas-mediated apoptosis and HIV plasma vire-
mia, our findings also offer a firm basis to explain why B
cells of HIV-viremic patients are dysfunctional. In this re-
gard, with an abnormally high percentage of B cells that are
destined to terminal differentiation and apoptosis, HIV-
viremic patients are less likely to respond adequately to an-
tigenic stimulation. Finally, our findings also suggest that B
cells of HIV-viremic patients lose responsiveness to BlyS-
mediated survival signals as a result of activation-induced
down-regulation of the main BlyS receptor, BAFF-R.
The increased expression of the death receptor CD95
and decreased expression of the survival receptor BAFF-R
would be predicted to cause a net decrease in B cell num-
bers in the setting of ongoing HIV replication. The cur-
rent work did not address this issue directly because its
cross-sectional nature and the large donor-to-donor vari-
ability in total B cell numbers observed both in HIV-
infected and HIV-negative donors were unlikely to yield
conclusive results. These limitations were further com-
pounded by complex and controversial issues of increased
cell turnover and tissue redistribution associated with HIV
viremia, which have been reported mainly for CD4  T
cells, but also suggested for B cells (49, 50). Nonetheless,
when total B cell numbers were analyzed from a well-con-
trolled longitudinal study of HIV-infected patients who cy-
cled off (4 wk) and on (8 wk) antiretroviral therapy, a sig-
nificant inverse correlation was observed between total B
cell numbers in peripheral blood and HIV plasma viremia
in seven out of nine patients who were on study for a min-
imum of 60 wk (reference 51 and unpublished data).
Hence, despite the increased B cell turnover associated
with ongoing HIV replication, there exists clear evidence
that it is offset by increased B cell death, possibly as a result
of modulations in the expression of TNFSF receptors such
as CD95 and BAFF-R.
The roles of recently identified members of the TNFSF
of receptors BCMA, TACI, and BAFF-R in B cell survival
and proliferation remain nebulous in humans and only par-
tially defined in mice (52, 53). Although a prominent role
for BAFF-R in the development of B cells in mice has
been definitively shown with BAFF-R–deficient mice
(54), similar targeted deficiencies in BCMA and TACI
have failed to demonstrate a clear role for these two recep-
tors in B cell development (55–58). Three of these studies
found B cell hyperactivity in the TACI-deficient mice,
suggesting that TACI is a negative regulator of B cell func-
tion (56–58). However, TACI-deficient mice have also
been shown to be deficient in T-independent humoral re-
sponses (56, 57), suggesting that TACI may be necessary
for certain functions. In human B cells, the triggering of
TACI with agonistic antibodies (NF- B inducing) has
been shown to interfere with CD40-mediated B cell prolif-
eration, suggesting TACI may also deliver inhibitory sig-
nals in human B cells (58).
In this work, we observed a pattern of expression of the
BLyS receptors BCMA, TACI, and BAFF-R that was
clearly modulated by HIV plasma viremia. B cells of HIV-
viremic patients expressed increased levels of BCMA, vari-
able levels of TACI, and decreased levels of BAFF-R when
compared with HIV-aviremic patients and HIV-negative
individuals. These observations are consistent with findings
showing that when B cells undergo terminal differentiation
in vitro, they undergo the same BLyS receptor modulations
as those described in the HIV-viremic patients (40). Also,
in agreement with a recent paper describing much stronger
binding kinetics between BLyS and BAFF-R than between
BLyS and BCMA (46), we found that levels of BAFF-R
expression dictated levels of BLyS binding, regardless of in-
creases in TACI and BCMA expression. Furthermore, the
loss of BLyS-binding on CD21low B cells of HIV-viremic
patients also translated into a loss in BLyS-mediated sur-
vival, as indicated by increased apoptosis of CD21low com-
pared with CD21high B cells in response to BLyS. Current
efforts are underway to further evaluate the consequences
of modulations in the expression of BCMA, TACI, and
BAFF-R relative to responsiveness to the BLyS-related
ligand APRIL, which binds BCMA and TACI, but not
BAFF-R (54, 59).
The extensive phenotyping performed to better charac-
terize the differentiation stage of B cells of HIV-viremic
patients further established a pattern of expression that was
clearly delineated by CD21 expression. It should be noted
that we found no evidence that the CD21low population of
B cells in HIV-viremic patients was any different pheno-
typically than the CD21low B cells of HIV-aviremic patients
and HIV-negative donors; this population was merely
overrepresented in HIV-viremic patients compared with
the two other groups. Irrespective of disease status, the
CD21low population was always more susceptible to apop-
tosis than its CD21high counterpart (Fig. 4 A). The B cell
surface markers that were found to be up-regulated in
HIV-viremic patients at the gene expression level were alsoRole of TNF Receptors in Survival of B Cells of HIV-viremic Patients 596
found to be up-regulated at the protein level on the
CD21low B cells. Consistent with published literature on
the phenotypic profile of plasma cells (38, 60, 61), B cells
of HIV-viremic patients exhibited many of the same char-
acteristic features, including reduced expression of CD20,
CD21, CD22, and CD25, as well as increased expression of
BCMA, CD38, CXCR3, CD27, and CD86, with the
CD21low fraction accounting for most of these modula-
tions. In contrast, certain B cell markers that are down-reg-
ulated on plasma cells were not found to be down-regu-
lated on B cells of HIV-viremic patients, including HLA-DR
and surface Ig, or in the case of CD20, were down-
regulated on a subset of CD21low B cells. CD27 has been
shown to be decreased on B cells of HIV-infected patients
(62, 63). However, these studies did not focus on the pa-
tients with detectable HIV plasma viremia, and we did not
focus on patients with very low CD4  T cell counts who
do have a paucity of CD27-expressing B cells (unpublished
data). CD22 was also discordant in that, whereas a fraction
of CD21low B cells of viremic patients expressed reduced
levels of CD22, consistent with features of plasma cells, an-
other fraction expressed higher than normal intensities of
CD22 (Fig. S1). Preliminary observations also indicated
that expression of CD138 and the transcription factor
Blimp-1, hallmarks of plasma cell differentiation (64), was
not substantially modulated in and on B cells of HIV-
viremic patients (unpublished data). However, considering
the variability in the expression of these factors in primary
human B cells and the heterogeneity of B cells in the pe-
ripheral blood (38, 65, 66), further investigation is needed.
Nonetheless, the differences clearly delineated in this work
suggest that B cells of viremic patients have a unique differ-
entiation pathway and/or become engaged in terminal dif-
ferentiation, but do not complete the process. Finally, the
levels of CD95 observed on B cells of HIV-viremic pa-
tients were higher than those reported for blood-derived
plasma cells (38), suggesting that the IFN-stimulated com-
ponent of responses to viruses that affects CD95 expression
may be imparting certain nonplasma cell features in HIV-
viremic patients.
The up-regulation of ISGs appears to be an observation
common not only to viral infections but also to other
pathologic conditions, including inflammatory diseases such
as SLE (34) and malignancies associated with high cell
turnover (67). Of note, the loss of CD21 expression has
also been observed on B cells of patients with inflammatory
diseases such as SLE and rheumatoid arthritis (68, 69), but
not on B cells of patients with hepatitis C virus infection
(70), a viral infection that is often compared with HIV with
regard to chronically high viral loads. Hence, it is difficult
to establish which of the three factors, namely viral, inflam-
matory, or terminal differentiation, had a predominant ef-
fect on the B cells of HIV-viremic patients. Of note, early
histological studies on tissues from HIV-infected patients
found evidence of lupus inclusions or cisternae in the lym-
phoid sections (36), and these same intracellular formations
were later reproduced by treating B cell lines with type I
IFNs (71), and more recently these inclusions were ob-
served in B cells isolated from HIV-viremic patients (Oren-
stein, J.M., personal communication). Several components
of these inclusions were found to be up-regulated in B cells
of HIV-viremic patients, providing a potential explanation
for observations made  15 yr ago and further associating
ongoing viral replication with morphological abnormalities
of B cells.
In conclusion, we have combined DNA microarray data
with phenotypic and functional analyses to establish a clear
pattern of B cell dysregulation in HIV-viremic patients.
This work supports and considerably extends our previous
findings that HIV-mediated hyperactivation induces B cell
terminal differentiation that is characterized by loss of
CD21 expression, reduced proliferative potential, increased
immunoglobulin secretion, and appearance of plasmacytoid
features. The gene expression profiles described herein are
consistent with the notion that HIV-mediated hyperactiva-
tion engages B cells along a pathway related to terminal dif-
ferentiation. Furthermore, in validating the microarray data
with phenotypic data, we find that the majority of aber-
rantly expressed cell surface markers are associated with the
CD21low population of B cells that is enriched in HIV-
viremic patients, diminished in HIV-aviremic patients, and
mostly absent in HIV-negative individuals. Finally, we find
that CD21low B cells of HIV-viremic patients, through
shifts in expression of TNFSF receptors CD95, BCMA,
and BAFF-R, may become more susceptible to cell death
and less responsive to survival signals. Increased CD95 ex-
pression and correspondingly increased Fas-mediated apop-
tosis are unique features of the B cell activation profile in
HIV-viremic patients as this death receptor is an ISG and
not a receptor associated with terminal differentiation (33,
38). Together, the combination of gene expression profil-
ing with phenotypic and functional analyses have enabled
us to gain a clear understanding of the pathways that drive
B cell dysfunction in HIV-viremic patients and offer new
information on avenues that could be considered to reverse
these pathways.
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